Cargando…
Serial change of C1 inhibitor in patients with sepsis: a prospective observational study
BACKGROUND: C1 inhibitor (C1-INH), which belongs to the superfamily of serine protease inhibitors, regulates the complement system and also the plasma kallikrein-kinin, fibrinolytic, and coagulation systems. The biologic activities of C1-INH can be divided into the regulation of vascular permeabilit...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032562/ https://www.ncbi.nlm.nih.gov/pubmed/30002833 http://dx.doi.org/10.1186/s40560-018-0309-5 |
_version_ | 1783337525562048512 |
---|---|
author | Hirose, Tomoya Ogura, Hiroshi Takahashi, Hiroki Ojima, Masahiro Jinkoo, Kang Nakamura, Youhei Kojima, Takashi Shimazu, Takeshi |
author_facet | Hirose, Tomoya Ogura, Hiroshi Takahashi, Hiroki Ojima, Masahiro Jinkoo, Kang Nakamura, Youhei Kojima, Takashi Shimazu, Takeshi |
author_sort | Hirose, Tomoya |
collection | PubMed |
description | BACKGROUND: C1 inhibitor (C1-INH), which belongs to the superfamily of serine protease inhibitors, regulates the complement system and also the plasma kallikrein-kinin, fibrinolytic, and coagulation systems. The biologic activities of C1-INH can be divided into the regulation of vascular permeability and anti-inflammatory functions. The objective of this study was to clarify the serial change of C1-INH in patients with sepsis and evaluate the relationship with the shock severity. METHODS: This was a single-center, prospective, observational study. We serially examined C1-INH activity values (normal range 70–130%) in patients with sepsis admitted into the intensive care unit of the Trauma and Acute Critical Care Center at Osaka University Hospital (Osaka, Japan) during the period between January 2014 and August 2015. We defined “refractory shock” as septic shock unresponsive to conventional therapy such as adequate fluid resuscitation and vasopressor therapy to maintain hemodynamics. RESULTS: Serial changes of C1-INH were evaluated in 40 patients with sepsis (30 men, 10 women; 30 survivors, 10 non-survivors; mean age, 70 ± 13.5 years). We divided the patients into three groups: non-shock group (n = 14), non-refractory shock group (n = 13), and refractory shock group (n = 13: 3 survivors, 10 non-survivors). In the non-shock group, C1-INH was 107.3 ± 26.5% on admission and 104.2 ± 22.3% on day 1, and it increased thereafter to 128.1 ± 26.4% on day 3, 138.3 ± 21.2% on day 7, and 140.3 ± 12.5% on day 14 (p < 0.0001). In the non-refractory shock group, C1-INH was 113.9 ± 19.2% on admission, 120.2 ± 23.0% on day 1, 135.7 ± 19.9% on day 3, 138.8 ± 17.2% on day 7, and 137.7 ± 10.7% on day 14 (p < 0.0001). In the refractory shock group, C1-INH was 96.7 ± 15.9% on admission, 88.9 ± 22.3% on day 1, 119.8 ± 39.6% on day 3, 144.4 ± 21.1% on day 7, and 140.5 ± 24.5% on day 14 (p < 0.0001). The difference between these three groups was statistically significant (p < 0.0001). C1-INH in non-survivors did not increase significantly during their clinical course (p = 0.0690). CONCLUSIONS: In refractory shock patients with sepsis, the values of C1-INH activity were lower (especially in non-survivors) on admission and day 1 as compared with non-shock and non-refractory shock patients. |
format | Online Article Text |
id | pubmed-6032562 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60325622018-07-12 Serial change of C1 inhibitor in patients with sepsis: a prospective observational study Hirose, Tomoya Ogura, Hiroshi Takahashi, Hiroki Ojima, Masahiro Jinkoo, Kang Nakamura, Youhei Kojima, Takashi Shimazu, Takeshi J Intensive Care Research BACKGROUND: C1 inhibitor (C1-INH), which belongs to the superfamily of serine protease inhibitors, regulates the complement system and also the plasma kallikrein-kinin, fibrinolytic, and coagulation systems. The biologic activities of C1-INH can be divided into the regulation of vascular permeability and anti-inflammatory functions. The objective of this study was to clarify the serial change of C1-INH in patients with sepsis and evaluate the relationship with the shock severity. METHODS: This was a single-center, prospective, observational study. We serially examined C1-INH activity values (normal range 70–130%) in patients with sepsis admitted into the intensive care unit of the Trauma and Acute Critical Care Center at Osaka University Hospital (Osaka, Japan) during the period between January 2014 and August 2015. We defined “refractory shock” as septic shock unresponsive to conventional therapy such as adequate fluid resuscitation and vasopressor therapy to maintain hemodynamics. RESULTS: Serial changes of C1-INH were evaluated in 40 patients with sepsis (30 men, 10 women; 30 survivors, 10 non-survivors; mean age, 70 ± 13.5 years). We divided the patients into three groups: non-shock group (n = 14), non-refractory shock group (n = 13), and refractory shock group (n = 13: 3 survivors, 10 non-survivors). In the non-shock group, C1-INH was 107.3 ± 26.5% on admission and 104.2 ± 22.3% on day 1, and it increased thereafter to 128.1 ± 26.4% on day 3, 138.3 ± 21.2% on day 7, and 140.3 ± 12.5% on day 14 (p < 0.0001). In the non-refractory shock group, C1-INH was 113.9 ± 19.2% on admission, 120.2 ± 23.0% on day 1, 135.7 ± 19.9% on day 3, 138.8 ± 17.2% on day 7, and 137.7 ± 10.7% on day 14 (p < 0.0001). In the refractory shock group, C1-INH was 96.7 ± 15.9% on admission, 88.9 ± 22.3% on day 1, 119.8 ± 39.6% on day 3, 144.4 ± 21.1% on day 7, and 140.5 ± 24.5% on day 14 (p < 0.0001). The difference between these three groups was statistically significant (p < 0.0001). C1-INH in non-survivors did not increase significantly during their clinical course (p = 0.0690). CONCLUSIONS: In refractory shock patients with sepsis, the values of C1-INH activity were lower (especially in non-survivors) on admission and day 1 as compared with non-shock and non-refractory shock patients. BioMed Central 2018-07-04 /pmc/articles/PMC6032562/ /pubmed/30002833 http://dx.doi.org/10.1186/s40560-018-0309-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Hirose, Tomoya Ogura, Hiroshi Takahashi, Hiroki Ojima, Masahiro Jinkoo, Kang Nakamura, Youhei Kojima, Takashi Shimazu, Takeshi Serial change of C1 inhibitor in patients with sepsis: a prospective observational study |
title | Serial change of C1 inhibitor in patients with sepsis: a prospective observational study |
title_full | Serial change of C1 inhibitor in patients with sepsis: a prospective observational study |
title_fullStr | Serial change of C1 inhibitor in patients with sepsis: a prospective observational study |
title_full_unstemmed | Serial change of C1 inhibitor in patients with sepsis: a prospective observational study |
title_short | Serial change of C1 inhibitor in patients with sepsis: a prospective observational study |
title_sort | serial change of c1 inhibitor in patients with sepsis: a prospective observational study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032562/ https://www.ncbi.nlm.nih.gov/pubmed/30002833 http://dx.doi.org/10.1186/s40560-018-0309-5 |
work_keys_str_mv | AT hirosetomoya serialchangeofc1inhibitorinpatientswithsepsisaprospectiveobservationalstudy AT ogurahiroshi serialchangeofc1inhibitorinpatientswithsepsisaprospectiveobservationalstudy AT takahashihiroki serialchangeofc1inhibitorinpatientswithsepsisaprospectiveobservationalstudy AT ojimamasahiro serialchangeofc1inhibitorinpatientswithsepsisaprospectiveobservationalstudy AT jinkookang serialchangeofc1inhibitorinpatientswithsepsisaprospectiveobservationalstudy AT nakamurayouhei serialchangeofc1inhibitorinpatientswithsepsisaprospectiveobservationalstudy AT kojimatakashi serialchangeofc1inhibitorinpatientswithsepsisaprospectiveobservationalstudy AT shimazutakeshi serialchangeofc1inhibitorinpatientswithsepsisaprospectiveobservationalstudy |